Prestige Consumer Healthcare Inc
NYSE:PBH
Prestige Consumer Healthcare Inc
NYSE:PBH
Price:
71.26 USD
0.2%
Market Closed
Updated:
May 3, 2024
P/FCFE
Price to FCFE
Price to FCFE
-58.5
Current
14
Median
23.2
Industry
Lower
than median
Lower
than industry value
Price to Free Cash Flow To Equity (P/FCFE) ratio is a valuation multiple that compares a company’s market capitalization to the amount of free cash flow available for equity shareholders. This metric is very similar to the P/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
P/FCFE
=-58.5
Market Cap
/
3.5B
FCFE
-60.5m
All Countries
| Market Cap | P/FCFE | ||||
|---|---|---|---|---|---|
| US |
|
Prestige Consumer Healthcare Inc
NYSE:PBH
|
3.5B USD | -58.5 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -40 845 137.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
717.6B USD | 138.7 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 57.1 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 2 143.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.9B USD | 28.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
324.7B USD | 25.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
188.4B GBP | 53.7 | |
| CH |
|
Novartis AG
SIX:NOVN
|
181.7B CHF | 22 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
170.7B CHF | 17.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.4B USD | 4.3 |
P/FCFE Forward Multiples
Forward P/FCFE multiple is a version of the P/FCFE ratio that uses forecasted free cash flow to equity for the P/FCFE calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/FCFE
N/A
2-Years Forward
P/FCFE
N/A
3-Years Forward
P/FCFE
N/A
You don't have any saved screeners yet
